GSK and Theravance set sights on early LABA/LAMA combo filing
This article was originally published in Scrip
Executive Summary
Top-line data from four 24-week studies of GlaxoSmithKline and Theravance's LABA/LAMA combination are positive enough to warrant slightly earlier than planned global filings for regulatory approval for the treatment of chronic obstructive pulmonary disease (COPD) starting at the end of this year, the companies say. The markets responded mildly but positively to the news, with GSK's share price rising 1.7%, adding around £1.23 billion ($1.93 billion) to the company's market valuation.